CMV

AiCuris’ Letermovir (AIC246) has met its primary efficacy endpoints in a Phase 2 trial for the control of human cytomegalovirus (HCMV) prophylaxis in human blood precursor cell (HBPC) recipients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Letermovir is a highly active and specific inhibitor of HCMV that acts against viruses which are resistant to invariably inhibitors of the viral polymerase.

The placebo-controlled dose-ranging Phase 2 trial included 133 HCMV-seropositive allogeneic HBPC recipients who were given 120mg and 240mg doses of Letermovir once-daily for 84 days.

In the trial, the primary efficacy endpoints are defined as incidence and time to onset of HCMV prophylaxis failure.

The Letermovir treated groups showed considerably lower incidence of failure due to the efficacy failure of prophylaxis or discontinuation of treatment for any other reason prior to day 84 when compared to placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study demonstrated that incidence of HCMV prophylaxis failure among patients receiving treatment for at least seven days prior to HCMV replication was none for Letermovir 240mg compared to two patients for Letermovir 120mg.

In addition to excellent efficacy, Letermovir also showed superior tolerability and safety results for the control of HCMV in transplant patients.

"This study shows that Letermovir is a safe, effective treatment to prevent these infections. This is a major advance for the care of these immunocompromised patients," said Prof. Richard Champlin, director of the Bone Marrow Transplantation Center in Houston, Texas.

Dr. Marie Paule Richard, CMO of AiCuris, added: "On the basis of these encouraging efficacy and safety results with Letermovir in transplant recipients we are preparing phase III development."

AiCuris CEO Helga Ruebsamen-Schaeff concluded: "Due to the excellent safety and efficacy of our drug it should now be possible to offer prophylaxis against HCMV to all patients undergoing this procedure at the time of transplantation or even earlier, rather than taking the risk of waiting for an HCMV infection to occur, before starting treatment."

German-based AiCuris is focused on the development of resistance-breaking drugs against HCMV, Herpes, Hepatitis B, HIV and Hepatitis C, as well as resistant Gram positive and Gram negative bacterial infections.

Image: CMV infection of a lung pneumocyte. Photo: MarcoTolo.